Schizophrenia

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

Emraclidine fails to significantly reduce schizophrenia symptoms in phase 2 EMPOWER trials, with no statistical difference from placebo on PANSS score.

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

A study found people with schizophrenia have a 4-fold higher risk of sudden cardiac death compared to the general population, underscoring the need for cardiometabolic care.

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

While this analysis found social anhedonia may be a potential intervention for some, nonsocial cognition may have a significant role in social disconnection for those with schizophrenia.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

Schizophrenia experts discuss the stigma and misconceptions surrounding schizophrenia as well as current treatment options.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.